Jack A. Reynolds

Jack A. Reynolds, DVM, DACLAM, DACVP and FIATP is a Founding Partner and the Executive Chairman of AnaBios. He recently retired from Pfizer as Senior Vice President of R&D and Worldwide Head of Safety Sciences. With over 30 years in the pharmaceutical industry, he is a seasoned leader within the pharmaceutical industry, having made substantial contributions to numerous development programs and important drug approvals. At Pfizer, he defined and implemented a new paradigm to elucidate, understand, manage and mitigate the inherent risks of medicines. This had a profound impact on Pfizer’s early stage portfolio in reducing attrition, improving drug development effectiveness and expanding their R&D portfolio. This early de-risking of drug development programs is only now being emulated by others.

Dr. Reynolds has the reputation of an industry trailblazer from his extensive work and leadership in building partnerships with regulatory agencies, and through leadership roles in professional societies, industry executive groups and scientific organizations. He is the founder and former Advisory Board Chair of the Drug Safety Executive Council, which now includes a membership of almost 2000 industry professionals and plays an important cross-industry role in collaboratively evaluating, validating and qualifying new technologies for safety testing and decision making. He is board certified in both Veterinary Pathology and Laboratory Animal Medicine and is a Fellow of the International Academy of Toxicological Pathologists. Dr. Reynolds is currently an Adjunct Professor in the Division of Pharmacotherapy and Experimental Therapeutics at the School of Pharmacy, The University of North Carolina at Chapel Hill and is a member of the Scientific Advisory Committee of the Global Alliance for TB Drug Development. In 2004, Dr. Reynolds received a Washington State University Distinguished Alumnus Award for Research and Teaching.